Hans T H Tu1, Bruce C V Campbell1, Soren Christensen2, Patricia M Desmond2, Deidre A De Silva3, Mark W Parsons4, Leonid Churilov5, Maarten G Lansberg6, Michael Mlynash6, Jean-Marc Olivot6, Matus Straka6, Roland Bammer6, Gregory W Albers6, Geoffrey A Donnan5, Stephen M Davis1. 1. Department of Medicine and Neurology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic, Australia. 2. Department of Radiology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic, Australia. 3. Department of Neurology, Singapore General Hospital Campus, National Neuroscience Institute, Singapore. 4. Department of Neurology and Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia. 5. Florey Neurosciences Institutes, The University of Melbourne, Parkville, Victoria, Australia. 6. Department of Neurology and Neurological Sciences and the Stanford Stroke Center, Stanford University, Stanford, CA, USA.
Abstract
BACKGROUND: Atrial fibrillation is associated with greater baseline neurological impairment and worse outcomes following ischemic stroke. Previous studies suggest that greater volumes of more severe baseline hypoperfusion in patients with history of atrial fibrillation may explain this association. We further investigated this association by comparing patients with and without atrial fibrillation on initial examination following stroke using pooled multimodal magnetic resonance imaging and clinical data from the Echoplanar Imaging Thrombolytic Evaluation Trial and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution studies. METHODS: Echoplanar Imaging Thrombolytic Evaluation Trial was a trial of 101 ischemic stroke patients randomized to intravenous tissue plasminogen activator or placebo, and Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution was a prospective cohort of 74 ischemic stroke patients treated withintravenous tissue plasminogen activator at three to six hours following symptom onset. Patients underwent multimodal magnetic resonance imaging before treatment, at three to five days and three-months after stroke in Echoplanar Imaging Thrombolytic Evaluation Trial; before treatment, three to six hours after treatment and one-month after stroke in Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution. Patients were assessed with the National Institutes of Health Stroke Scale and the modified Rankin scale before treatment and at three-months after stroke. Patients were categorized into definite atrial fibrillation (present on initial examination), probable atrial fibrillation (history but no atrial fibrillation on initial examination), and no atrial fibrillation. Perfusion data were reprocessed with automated magnetic resonance imaging analysis software (RAPID, Stanford University, Stanford, CA, USA). Hypoperfusion volumes were defined using time to maximum delays in two-second increments from >4 to >8 s. Hemorrhagic transformation was classified according to the European Cooperative Acute Stroke Studies criteria. RESULTS: Of the 175 patients, 28 had definite atrial fibrillation, 30 probable atrial fibrillation, 111 no atrial fibrillation, and six were excluded due to insufficient imaging data. At baseline, patients with definite atrial fibrillation had more severe hypoperfusion (median time to maximum >8 s, volume 48 vs. 29 ml, P = 0.02) compared with patients with no atrial fibrillation. At outcome, patients with definite atrial fibrillation had greater infarct growth (median volume 47 vs. 8 ml, P = 0.001), larger infarcts (median volume 75 vs. 23 ml, P = 0.001), more frequent parenchymal hematoma grade hemorrhagic transformation (30% vs. 10%, P = 0.03), worse functional outcomes (median modified Rankin scale score 4 vs. 3, P = 0.03), and higher mortality (36% vs. 16%, P = 0·.3) compared with patients with no atrial fibrillation. Definite atrial fibrillation was independently associated with increased parenchymal hematoma (odds ratio = 6.05, 95% confidence interval 1.60-22.83) but not poor functional outcome (modified Rankin scale 3-6, odds ratio = 0.99, 95% confidence interval 0.35-2.80) or mortality (odds ratio = 2.54, 95% confidence interval 0.86-7.49) three-months following stroke, after adjusting for other baseline imbalances. CONCLUSION: Atrial fibrillation is associated with greater volumes of more severe baseline hypoperfusion, leading to higher infarct growth, more frequent severe hemorrhagic transformation and worse stroke outcomes.
RCT Entities:
BACKGROUND:Atrial fibrillation is associated with greater baseline neurological impairment and worse outcomes following ischemic stroke. Previous studies suggest that greater volumes of more severe baseline hypoperfusion in patients with history of atrial fibrillation may explain this association. We further investigated this association by comparing patients with and without atrial fibrillation on initial examination following stroke using pooled multimodal magnetic resonance imaging and clinical data from the Echoplanar Imaging Thrombolytic Evaluation Trial and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution studies. METHODS:Echoplanar Imaging Thrombolytic Evaluation Trial was a trial of 101 ischemic strokepatients randomized to intravenous tissue plasminogen activator or placebo, and Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution was a prospective cohort of 74 ischemic strokepatients treated with intravenous tissue plasminogen activator at three to six hours following symptom onset. Patients underwent multimodal magnetic resonance imaging before treatment, at three to five days and three-months after stroke in Echoplanar Imaging Thrombolytic Evaluation Trial; before treatment, three to six hours after treatment and one-month after stroke in Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution. Patients were assessed with the National Institutes of Health Stroke Scale and the modified Rankin scale before treatment and at three-months after stroke. Patients were categorized into definite atrial fibrillation (present on initial examination), probable atrial fibrillation (history but no atrial fibrillation on initial examination), and no atrial fibrillation. Perfusion data were reprocessed with automated magnetic resonance imaging analysis software (RAPID, Stanford University, Stanford, CA, USA). Hypoperfusion volumes were defined using time to maximum delays in two-second increments from >4 to >8 s. Hemorrhagic transformation was classified according to the European Cooperative Acute Stroke Studies criteria. RESULTS: Of the 175 patients, 28 had definite atrial fibrillation, 30 probable atrial fibrillation, 111 no atrial fibrillation, and six were excluded due to insufficient imaging data. At baseline, patients with definite atrial fibrillation had more severe hypoperfusion (median time to maximum >8 s, volume 48 vs. 29 ml, P = 0.02) compared with patients with no atrial fibrillation. At outcome, patients with definite atrial fibrillation had greater infarct growth (median volume 47 vs. 8 ml, P = 0.001), larger infarcts (median volume 75 vs. 23 ml, P = 0.001), more frequent parenchymal hematoma grade hemorrhagic transformation (30% vs. 10%, P = 0.03), worse functional outcomes (median modified Rankin scale score 4 vs. 3, P = 0.03), and higher mortality (36% vs. 16%, P = 0·.3) compared with patients with no atrial fibrillation. Definite atrial fibrillation was independently associated with increased parenchymal hematoma (odds ratio = 6.05, 95% confidence interval 1.60-22.83) but not poor functional outcome (modified Rankin scale 3-6, odds ratio = 0.99, 95% confidence interval 0.35-2.80) or mortality (odds ratio = 2.54, 95% confidence interval 0.86-7.49) three-months following stroke, after adjusting for other baseline imbalances. CONCLUSION:Atrial fibrillation is associated with greater volumes of more severe baseline hypoperfusion, leading to higher infarct growth, more frequent severe hemorrhagic transformation and worse stroke outcomes.
Authors: Maarten G Lansberg; Jun Lee; Soren Christensen; Matus Straka; Deidre A De Silva; Michael Mlynash; Bruce C Campbell; Roland Bammer; Jean-Marc Olivot; Patricia Desmond; Stephen M Davis; Geoffrey A Donnan; Gregory W Albers Journal: Stroke Date: 2011-04-14 Impact factor: 7.914
Authors: Jong Hun Kim; Oh Young Bang; David S Liebeskind; Bruce Ovbiagele; Gyeong-Moon Kim; Chin Sang Chung; Kwang Ho Lee; Jeffrey L Saver Journal: Stroke Date: 2010-01-14 Impact factor: 7.914
Authors: Derek J Emery; Peter D Schellinger; Daniel Selchen; Andre G Douen; Richard Chan; Ashfaq Shuaib; Kenneth S Butcher Journal: Stroke Date: 2011-02-24 Impact factor: 7.914
Authors: Yoshinari Nagakane; Soren Christensen; Toshiyasu Ogata; Leonid Churilov; Henry Ma; Mark W Parsons; Patricia M Desmond; Christopher R Levi; Kenneth S Butcher; Stephen M Davis; Geoffrey A Donnan Journal: Stroke Date: 2012-04-12 Impact factor: 7.914
Authors: Hans T H Tu; Bruce C V Campbell; Soren Christensen; Marnie Collins; Deidre A De Silva; Kenneth S Butcher; Mark W Parsons; Patricia M Desmond; P Alan Barber; Christopher R Levi; Christopher F Bladin; Geoffrey A Donnan; Stephen M Davis Journal: Cerebrovasc Dis Date: 2010-08-05 Impact factor: 2.762
Authors: Hans T H Tu; Bruce C V Campbell; Leonid Churilov; Jonathan M Kalman; Kennedy R Lees; Patrick D Lyden; Ashfaq Shuaib; Geoffrey A Donnan; Stephen M Davis Journal: Cerebrovasc Dis Date: 2011-10-14 Impact factor: 2.762
Authors: Sandeep Panikker; Joanne Lord; Julian W E Jarman; Shannon Armstrong; David G Jones; Shouvik Haldar; Charles Butcher; Habib Khan; Lilian Mantziari; Edward Nicol; Wajid Hussain; Jonathan R Clague; John P Foran; Vias Markides; Tom Wong Journal: Eur Heart J Date: 2016-03-01 Impact factor: 29.983
Authors: Caty Carrera; Natalia Cullell; Nuria Torres-Águila; Elena Muiño; Alejandro Bustamante; Antonio Dávalos; Elena López-Cancio; Marc Ribó; Carlos A Molina; Eva Giralt-Steinhauer; Carolina Soriano-Tárraga; Marina Mola-Caminal; Jordi Jiménez-Conde; Jaume Roquer; Cristófol Vives-Bauza; Rosa Díaz Navarro; Victor Obach; Juan Francisco Arenillas; Tomás Segura; Gemma Serrano-Heras; Joan Martí-Fàbregas; Marimar Freijo; Juan Antonio Cabezas; Turgut Tatlisumak; Laura Heitsch; Laura Ibañez; Carlos Cruchaga; Jin-Moo Lee; Daniel Strbian; Joan Montaner; Israel Fernández-Cadenas Journal: Neurology Date: 2019-07-31 Impact factor: 9.910
Authors: Chuanhui Dong; Kefeng Wang; Marco R Di Tullio; Carolina Gutierrez; Sebastian Koch; Enid J García; Juan Carlos Zevallos; Ulises Nobo; Ryan C Martin; W Scott Burgin; David Z Rose; Jose G Romano; Jeffrey J Goldberger; Ralph L Sacco; Tatjana Rundek Journal: Int J Cerebrovasc Dis Stroke Date: 2019-07-22